TRVI – trevi therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer
Trevi Therapeutics (NASDAQ:TRVI) was upgraded by analysts at B. Riley to a "strong-buy" rating.
Trevi Therapeutics (NASDAQ:TRVI) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
Trevi Therapeutics: Big Cough Data, Bigger Execution Risk [Seeking Alpha]
How Trevi Therapeutics' (TRVI) Phase 3 Progress and Fresh Funding May Influence Investor Expectations [Yahoo! Finance]
Form 8-K Trevi Therapeutics, Inc. For: Dec 01
Form 4 Trevi Therapeutics, Inc. For: Dec 02 Filed by: Galletta Christopher
Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: Frazier Life Sciences Public Fund, L.P.
Form SCHEDULE 13G Trevi Therapeutics, Inc. Filed by: BlackRock, Inc.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.